drug protocol number

1F-MC-B007

drug sponsor

Eli Lilly

drug study

Any biologic therapy (including biosimilars) available on the market and prescribe to patients within routine care

drug trial site

Hira Hospital (Makkah)

drug status

Ongoing

drug phase